Drug Profile
Research programme: phytocannabinoid-based therapeutics - India Globalization Capital
Alternative Names: Hyalolex; IGC-503; IGC-504; IGC-506; SerosapseLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator University of South Florida
- Developer India Globalization Capital
- Class Analgesics; Antidementias; Antiepileptic drugs; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Cannabinoids
- Mechanism of Action Cannabinoid receptor CB1 modulators; Cannabinoid receptor CB2 modulators; G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cachexia; Cancer pain; Eating disorders; Epilepsy; Neuropathic pain; Parkinson's disease; Post-traumatic stress disorders
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 28 May 2021 No recent reports of development identified for preclinical development in Cachexia in USA
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer-pain in USA